Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, Ray Blanco’s FDA Trader, Penny Pot Profits and Technology Profits Daily. Ray has been with Seven Figure Publishing for nine years. In 2018, his closed positions in Technology Profits Confidential averaged over 100% gains.
Every year, the American Society of Clinical Oncology hosts a conference on cancer. Thousands show up to hear from cancer researchers on the cutting edge and to learn about the latest and greatest therapies being created to vanquish this deadly suite of diseases. It's also a place where biotechnology and pharmaceutical companies large and small show off the potential of their wares.
Once-obscure 20th-century researchers messing around with fungi and bacteria organisms completely upended the medical apple cart when they discovered how these organisms fought off the competition. Since other bacteria often fed upon the same stuff as these organisms, they had adapted a way to kill them off. These discoveries, when applied to human bacterial infections, represented the greatest biomedical achievement since the discovery of vaccines. We took these naturally occurring antibiotics, figured out how to mass-produce them and changed health care forever. Infections that once killed millions of people no longer had to.
It's only 4 millimeters square and less than a millimeter thick, but this little chip does something that would have required bulky, expensive sensors not too many years ago. Thanks to advances in microelectromechanical systems (MEMS) technology, these chips can accurately sense changes in acceleration and position in a compact, energy-efficient package.
Most of the 19th and the first half of the 20th century were all about building things bigger. From skyscrapers to transoceanic steam-powered cruisers, bigger tech meant better. But in the past few decades, there's been a "ramp up" in tiny machine efficiency... and it's about to reach an inflection point in the markets. Ray Blanco has more...
Flash Action Alert: In This Market, It’s Important to Avoid Losses. Take Profits on This Former Highflier
The biotech market has been, as you know, quite difficult lately. Many formerly high flying biotechnology companies have seen their market values halved—or worse. In many cases this has happened in absence of any negative news whatsoever.
A lot can change in a month, especially with biotech stocks. Back in mid-March, one of our stock’s shares were in the midteens. Then, a European regulatory committee recommended approval for our company’s lead drug, vintafolide, to treat ovarian cancer in patients that have become resistant to platinum-based therapies. Shares nearly doubled on the news, and we recommended selling half of our shares to secure a 266% return and hedge against future risks.
Cancer research has come a long way in a very short amount of time. But it still has a long way to go. Today, Ray Blanco explains why cancer research could make leaps and bounds in the coming years, and how early investors could make a fortune because of it. Read on...
It's been rough for biotechnology stocks. The Nasdaq Biotechnology Index was down 20% early last week from its late February peak. The S&P Biotechnology index was off even worse, down 26%. These indexes have now come back some 6% and 4%, respectively. But the indexes don't capture the bloodbath that has hit smaller, more speculative names. These are generally biotechnology companies that are still in the development phase and aren't generating significant revenues.
It's easy to forget that despite the current state of the markets in general, and biotechnology stocks in particular, many small biotechs are still moving their products from the lab and clinic to the market. In the biotech world, this is the road to profitability and share appreciation over time.
Hardest hit are smaller biotechnology companies that aren't yet generating revenues. This, of course, includes some our past portfolio recommendations. We took profits on several of them late last and early this year. All three of these companies have seen their shares sell off sharply from recent peaks, along with much of the rest of the biotechnology market. Our March pick, for example, is still languishing below our buy price. The recent sell-off provides an opportunity to buy shares cheap.